Navigation Links
New Cancer Treatments and Combination Therapies Presented by Leading Experts from the John Theurer Cancer Center at the American Society of Clinical Oncology Annual Meeting
Date:6/3/2010

udy is still ongoing, the researchers found that MIPI did not identify the three distinct staging categories with respect to patients' overall survival or progression-free survival, the primary endpoints for this study. Dr. Mato and colleagues are collaborating with another center to verify their results. Future work will focus on identifying molecular markers for failure in mantle cell lymphoma patients treated with dose-intensive regimens.

Vorinostat proves safe and tolerable for treating various cancers. (Abstract number e13600; publication-only abstract)

David S. Siegel, M.D., Ph.D., Co-Chief, Multiple Myeloma at the John Theurer Cancer Center and colleagues will present their analyses of safety and tolerability data from Phase I and II studies of vorinostat. Vorinostat is a medication that is FDA approved to treat skin problems related to cutaneous T-cell lymphoma when other treatments have not been effective. It is a histone deacetylase (HDAC) inhibitor, the first in a class of drugs that regulate enzymes involved in cell signaling. Vorinostat is also being investigated as a treatment option for a range of other solid and hematologic malignancies.

The researchers looked at safety and tolerability data from patients in phase I and II Merck-sponsored clinical trials who received vorinostat as a single (monotherapy) or combination therapy for a variety of cancers. Data from these unblinded trials showed that vorinostat has an acceptable safety and tolerability profile when given as monotherapy, or more commonly in a combination regimen, for patients with refractory metastatic cancer.

Denileukin diftitox shows promise for newly diagnosed T-cell lymphoma patients (the CONCEPT trial). (Abstract number 8045; poster session, June 4, 5:00 –

SOURCE John Theurer Cancer Center
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Studies Demonstrate Early Stage Detection and Economic Benefits of a Blood-Based Test for Lung Cancer
2. Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
3. Health Robotics South East Asia Wins two key Cancer Therapy Outsourcing Projects in Malaysia and Thailand
4. NewLink Initiates Pivotal Phase 3 Clinical Trial of HyperAcute(R)-Pancreas Immunotherapy for Resected Pancreatic Cancer
5. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Pancreatic Cancer Clinical Trial
6. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
7. Oncolytics Biotech(R) Inc. Announces Opening of Enrollment in Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
8. Tumor-Targeted Rexin-G Prolongs Survival in Gemcitabine-Resistant Metastatic Pancreas Cancer in Advanced Phase I and II Studies (ASCO 2010)
9. Tumor-Targeted Nanoparticle-based Gene Delivery Provides Evidence of Therapeutic Vaccination in Patients with Metastatic Cancer (ASCO 2010)
10. Abviva Details Patent Information for its Breast Cancer Risk Assessment Technology
11. Oncolytics Biotech(R) Inc. Announces Phase I Colorectal Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... , April 23, 2015 WuXi PharmaTech ... R&D capability and technology platform company serving the pharmaceutical, ... China and the United ... financial results for the first quarter of 2015 after ... 13, 2015 (which will be Thursday morning, May 14, ...
(Date:4/23/2015)... 2015  Veracyte, Inc. (NASDAQ: VCYT ) today ... to sell approximately $40 million of its common stock ... will purchase an aggregate of 4,907,975 shares of common ... the closing stock price on April 22, 2015. The ... including Broadfin Capital, Camber Capital, Deerfield, Longwood Capital Partners ...
(Date:4/23/2015)... Proove Biosciences , a ... excited to announce the launch of Proove ... assesses 62 genetic variations to predict good versus ... prescribed non-opioid pain medications, namely ibuprofen (brand name ... name Xanax) and acetaminophen (brand name Tylenol). ...
(Date:4/23/2015)... April 23, 2015 /PRNewswire/ - Crystal Research Associates, LLC ... Overview ® (EIO) on Aeterna Zentaris Inc. (NASDAQ: ... available on Crystal Research Associates, website at ... website at www.aezsinc.com . Aeterna Zentaris ... biopharmaceutical company in oncology, endocrinology, and women,s health. With ...
Breaking Biology Technology:WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 2WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 3Veracyte, Inc. Announces $40 Million Private Placement 2Veracyte, Inc. Announces $40 Million Private Placement 3Veracyte, Inc. Announces $40 Million Private Placement 4Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 2Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 3Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on Aeterna Zentaris Inc. 2Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on Aeterna Zentaris Inc. 3
... with minimal patient discomfort, SPOKANE, Wash., Nov. ... launch of the ComforTen(TM) Multiple Skin,Test System, its ... steel 1.2mm lancet tips, which create minimal skin ... 10-test, self-loading,surgical steel testing device on the market. ...
... NEW YORK, Nov. 9 Lev Pharmaceuticals, Inc.,(OTC Bulletin Board: LEVP.OB) today announced ... 13, 2007, at 1:00,p.m. Eastern Time (ET), in conjunction with the release of ... financial results at 7:00 a.m. ET on Tuesday, November 13,2007. DATE: ... 2007 TIME: ...
... Cadence Pharmaceuticals,Inc. (Nasdaq: CADX ), a ... product candidates principally,for use in the hospital setting, ... ended September 30, 2007 financial results after the ... Cadence management will host a conference call and ...
Cached Biology Technology:HollisterStier Offers Comfort With New ComforTen(TM) Multiple Skin Testing Device 2HollisterStier Offers Comfort With New ComforTen(TM) Multiple Skin Testing Device 3Lev Pharmaceuticals Invites You to Participate in its Q3'07 Earnings Results Conference Call and Webcast 2Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2007 Financial Results 2
(Date:3/20/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces its biometric payment ... products featured in 2015 "I Want That" International CES ... on the DIY Network.   DIY,s "I ... , site of the 2015 International CES for a ...
(Date:3/19/2015)... 19, 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, announces its biometric payment technology, ... that aired this week on Washington DC,s ... In a segment "The Next Great Thing", host Laura ... to pay, and ,a really big breakthrough in mobile payment.,  ...
(Date:3/17/2015)... Minn. , March 17, 2015 ... technology company specializing in clinical study management systems, ... be in attendance at ARENA,s Outsourcing in Clinical ... NC.  This event provides an excellent forum for ... easy-to-use, flexible and affordable software-as-a-service (SaaS) eClinical technology ...
Breaking Biology News(10 mins):NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
... January 21, JoVE, the Journal of Visualized Experiments ... that explored one of the most intriguing research questions ... The protocol, titled Conducting Miller-Urey Experiments, is comprised of ... by Dr. Stanley Miller and Dr. Harold Urey in ...
... in the early stages of multiple sclerosis (MS), low levels ... and hasten its progression, according to a new study led ... with Bayer HealthCare. The findings suggest that patients in the ... increasing their vitamin D intake. "Because low vitamin D ...
... longs fora master key that allows them to escape. A study ... how a protein that promotes tumor growth also enables cancer cells ... a blood or lymphatic vessel, a cancer cell is imprisoned in ... tumor cell,s master key. It loosens connections between endothelial cells that ...
Cached Biology News:A 21st century adaptation of the Miller-Urey origin of life experiments 2Boosting vitamin D could slow progression, reduce severity of multiple sclerosis 2FAK helps tumor cells enter the bloodstream 2
... and Non-ionic Detergent Removal , ... selective, virtually no cross-reactivity with other proteins ... pellet , Economical new surface technology, ... can often interfere with protein analysis. SurfactAway ...
Physical Form: saline suspension with ethanol Particle Dim: mean particle size 50 μm Matrix: HyperD F. Useful for the removal of detergents from protein samples....
... workstation automates a wide array of research ... Sample Preparation to Bio-Molecular and Cell Based ... the Caliper Sciclone enables numerous combinations of ... the needs of a given application, and ...
General description: MaxiSorp TM surface is ideal for arraying molecules with mixed hydrophilic/hydrophobic domains such as proteins ID clarifier: Maxisorp(tm) with lid...
Biology Products: